on Biophytis (EPA:ALBPS)
Biophytis Temporarily Suspends Trading of Shares Before Refinancing
On January 6, 2025, Biophytis SA, a biotechnology firm specializing in treatments for age-related diseases, announced a temporary suspension of its shares and share warrants trading. This suspension affects its ordinary shares on the Euronext Growth market and American Depositary Shares on the OTC market. The company, based in Paris and with offices in Cambridge, USA, intends to lift the suspension upon detailing a planned refinancing transaction shortly.
Biophytis is advancing several drug candidates, notably BIO101 for muscular and other diseases. This move is seen as preparatory to financing efforts to further these clinical projects. Details of the refinancing will be unveiled when trading resumes in the coming days.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news